Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

Oral Presentation Details Dose Optimization of Pre-Clinical Otelixizumab Surrogate

NEW ORLEANS, June 8 /PRNewswire/ -- Tolerx, Inc., a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases, today presented results from a pre-clinical dose-optimization study conducted with a surrogate of its Phase 3 anti-CD3 monoclonal antibody, otelixizumab, at the 69th Scientific Sessions of the American Diabetes Association (ADA), which is continuing until June 9, 2009 in New Orleans, Louisiana.

The presentation (#297-OR), entitled "Dose Ranging Studies of an Anti-CD3 Antibody in NOD mice to Determine Minimum Effective Dose," was part of an Oral Session on Antigen-Specific and Non-Specific Regulation of Type 1 Diabetes. In the session, Dr. Devangi Mehta, Tolerx Senior Scientist, presented data demonstrating the effects of modified dosing regimens of the anti-CD3 monoclonal antibody in a commonly used non-obese diabetic (NOD) mouse model of autoimmune diabetes.

Tolerx researchers conducted dose-ranging studies to establish the minimum effective dose and to investigate pharmacodynamic (PD) parameters, including T-cell receptor (TCR) modulation, that correlate with efficacy in a preclinical model of diabetes. Evaluation of a dose of 8ug (0.0004mg/kg) of anti-CD3 antibody, a 30-fold reduction from previously investigated dosing regimens, induced up to 53% remission of diabetes, a response rate equivalent to those achieved with a 250ug (0.0125mg/kg) dosing regimen in other studies. This result demonstrates that lower doses of anti-CD3 monoclonal antibody, causing partial TCR modulation, are efficacious in this model, and that high doses resulting in full TCR modulation are not required to achieve similar rates of remission.

These data, combined with a rigorous Phase 2 clinical development program assessing more than 10 dosing regimens, have led
'/>"/>

SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... India , August 27, 2015 According ... Product (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, ... - Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling ... USD 411.5 Million in 2015, at a CAGR of 11.4 % ... 136 ma rket data T ables and ...
(Date:8/27/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the ... and patent-protected processes to develop and market advanced ... Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... inaccuracies in the press release issued by the ... from the Patent Trial and Appeal Board ("PTAB"). ...
(Date:8/27/2015)... According to a new market ... Standalone), by Deployment Mode (Web based, On-Premise, Cloud-Based), by ... Providers), by Component - Global Trends & Forecast to ... at $501.1 Million 2014, and is projected to reach ... from 2014 to 2019. Browse 60 ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... Pharmaceuticals, Inc. (NASDAQ: AMPE ) ("Ampio" or ... uses for previously approved drugs and new molecular entities ... of the allowance of two important U.S. patents. The ... compounds that combine elements of diketopiperazines (same class as ...
... 2011 Reportlinker.com announces that a new ... catalogue: X-ray Equipment - ... http://www.reportlinker.com/p0683626/X-ray-Equipment---Top-5-European-Markets.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging This package ... the following European countries: Germany, United Kingdom, ...
Cached Medicine Technology:Ampio Pharmaceuticals Expands Patent Portfolio of Drugs for Treating Inflammatory Diseases 2X-ray Equipment - Top 5 European Markets 2
(Date:8/27/2015)... , ... August 27, 2015 , ... ... instruments available for quantitative PCR (qPCR) in the last decade. New ... and reduced operating costs. On the flipside, where do lab managers, technicians, and ...
(Date:8/27/2015)... ... August 27, 2015 , ... Allegheny General ... just 20 adult-only medical centers in the United States to receive international recognition ... lungs. The Extracorporeal Life Support Organization (ELSO) , an international consortium of ...
(Date:8/27/2015)... , ... August 27, 2015 , ... The Naderi Center ... be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The first ... provides permanent results without surgery. Dr. Kulak is the only Board Certified surgeon ...
(Date:8/27/2015)... R.I. (PRWEB) , ... August 27, 2015 , ... More ... on a road trip. That’s why Amica Insurance is sharing some tips to help ... of America, about 30 million people travel with pets each year. Amica is sharing ...
(Date:8/27/2015)... London, UK (PRWEB) , ... ... ... Ltd and Black Swan Analysis signed a partnership agreement for quality market ... sell research reports elaborated by Black Swan Analysis. , Commenting on the ...
Breaking Medicine News(10 mins):Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 2Health News:Douglas Scientific® Webinar Outlines Comparisons of Varied qPCR Instruments 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 2Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 3Health News:International Organization Honors Allegheny General Hospital's Advanced Lifesaving Program for Cardiac and Respiratory Failure 4Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 2Health News:Market Publishers Ltd and Black Swan Analysis Sign Partnership Agreement 3
... treatments can be the worst news a cancer patient ... of Missouri-Columbia is working steadfastly to learn why some ... drug cisplatin, in hopes of identifying the particular genes ... as possible. , In a paper published in the ...
... adult suffers a cardiorespiratory arrest the rapid application of ... death in many cases. Nevertheless, defibrillation also has its ... from the moment of the attack, the possibilities of ... to avoid avoidable deaths, more and more easy-to-handle, automatic ...
... RICHMOND, Va., Oct. 2 Filtrona Fibertec, a ... and,manufacturer of custom fluid handling components, celebrated the ... Ningbo, China with a Grand Opening,celebration. (Logo: ... an increase of more than double the size ...
... California, October 2 joimax GmbH, Campbell,CA, is pleased ... Inc. the company is moving to larger premises in ... October 1st, 2007,joimax, Inc. will be located at ... CA 95008 USA "This move reflects the strong ...
... Nutrition Systems, LLC has added over,6,000 menu items ... dining,restaurant chains to http://www.NutritionPedia.com, the only ... find out the,nutritional content of their favorite menu ... dining and buffet style restaurants such as,Applebee,s Neighborhood ...
... Cements Position as Leading ,Single Source, Provider for ... Healthcare Technology Based Mobility ... Inc. (Nasdaq:,IFLG), a leading technology provider of mobile ... today that it has acquired,Healthcare Informatics Associates, Inc. ...
Cached Medicine News:Health News:MU researchers studying model to learn why certain cancers become resistant to drugs 2Health News:Algorithms to reanimate the heart 2Health News:Algorithms to reanimate the heart 3Health News:Filtrona Fibertec Ningbo, China Plant Celebrates Expansion 2Health News:NutritionPedia Adds Nutrition Facts for Over 6,000 Menu Items From 70 Leading Fast-Casual and Family Dining Restaurant Chains 2Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 2Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 3Health News:InfoLogix Acquires Healthcare Informatics Associates Inc. (HIA); Adds Premier Healthcare Consulting Firm and Systems Integrator 4
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic. Economical. Single use. Non-Sterile....
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
... Portex® Blue Line® uncuffed endotracheal ... or Murphy styles, in standard ... Line® adult and pediatric uncuffed ... implant-tested polyvinyl chloride with a ...
Medicine Products: